Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.

Scientific reports - 5 Apr 2024

Kim Yoo-Na, Chung Yun Soo, Park Eunhyang, Lee Seung Tae, Lee Jung-Yun

Abstract excerpt

Human epidermal growth factor receptor-2 (HER2)-targeting drugs are increasingly being incorporated into therapeutic paradigms for non-breast cancers, yet studies on HER2 expression in ovarian cancer (OC) are inadequate. Here, we studied the HER2 status and dynamic changes in OC by reviewing the records of patients who underwent HER2 testing at a single institution. Clinical parameters, including histology, BRCA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Mutation Rate
Share to Ovarian Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 38580676
DOI: 10.1038/s41598-024-57515-y
PMCID: PMC10997762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.PMID 38580676Read ↗

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies.Semantic proximity Read ↗

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.Semantic proximity Read ↗

The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study.Semantic proximity Read ↗

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.Semantic proximity Read ↗

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity Read ↗

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.Semantic proximity Read ↗

'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.Semantic proximity Read ↗

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.Semantic proximity Read ↗

Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.Semantic proximity Read ↗

Expression Profiling of the Ovarian Surface Kinome Reveals Candidate Genes for Early Neoplastic ChangesSemantic proximity Read ↗

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.Semantic proximity Read ↗

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.